DBV Technologies (France) Today
| DBV Stock | EUR 0.65 0.05 8.33% |
Performance0 of 100
| Odds Of DistressLess than 9
|
DBV Technologies is trading at 0.65 as of the 28th of November 2024, a 8.33% up since the beginning of the trading day. The stock's open price was 0.6. DBV Technologies has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for DBV Technologies SA are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France. DBV TECHNOLOGIES operates under Biotechnology classification in France and is traded on Paris Stock Exchange. The company has 93.97 M outstanding shares. More on DBV Technologies SA
Moving against DBV Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
DBV Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. DBV Technologies' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding DBV Technologies or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | MarieCatherine Therene |
| Thematic Idea | IT (View all Themes) |
| Business Concentration | IT, Health Care, Biotechnology, Biotechnology, Healthcare, Computing (View all Sectors) |
DBV Technologies SA (DBV) is traded on Euronext Paris in France and employs 85 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 269.31 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate DBV Technologies's market, we take the total number of its shares issued and multiply it by DBV Technologies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. DBV Technologies operates under Biotechnology sector and is part of Health Care industry. The entity has 93.97 M outstanding shares.
DBV Technologies SA has accumulated about 125.48 M in cash with (108.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.28, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check DBV Technologies Probability Of Bankruptcy
Ownership AllocationDBV Technologies holds a total of 93.97 Million outstanding shares. 30% of DBV Technologies SA outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Thus, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check DBV Ownership Details
DBV Technologies Risk Profiles
Although DBV Technologies' alpha and beta are two of the key measurements used to evaluate DBV Technologies' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.22 | |||
| Standard Deviation | 6.07 | |||
| Variance | 36.81 | |||
| Risk Adjusted Performance | (0.02) |
DBV Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in DBV Technologies without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamentals Comparison Now
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities |
| All Next | Launch Module |
DBV Technologies Corporate Directors
| Viviane Monges | Non-Executive Independent Director | Profile | |
| Claire Giraut | Non-Executive Independent Director | Profile | |
| Daniel Soland | Non-Executive Independent Director | Profile | |
| Julie ONeill | Non-Executive Director | Profile |
Other Information on Investing in DBV Stock
DBV Technologies financial ratios help investors to determine whether DBV Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DBV with respect to the benefits of owning DBV Technologies security.